Hemab Therapeutics (NASDAQ:COAG) Major Shareholder Acquires $152,973.94 in Stock

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) major shareholder Ra Capital Management, L.P. acquired 6,146 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were acquired at an average price of $24.89 per share, with a total value of $152,973.94. Following the completion of the transaction, the insider owned 6,383,114 shares in the company, valued at $158,875,707.46. The trade was a 0.10% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Tuesday, June 16th, Ra Capital Management, L.P. purchased 61,523 shares of Hemab Therapeutics stock. The stock was purchased at an average price of $24.98 per share, with a total value of $1,536,844.54.
• On Wednesday, May 20th, Ra Capital Management, L.P. acquired 996 shares of Hemab Therapeutics stock. The stock was acquired at an average price of $24.94 per share, with a total value of $24,840.24.
• On Tuesday, May 19th, Ra Capital Management, L.P. bought 3,802 shares of Hemab Therapeutics stock. The shares were bought at an average cost of $24.97 per share, for a total transaction of $94,935.94.
• On Tuesday, May 12th, Ra Capital Management, L.P. purchased 6,387 shares of Hemab Therapeutics stock. The stock was purchased at an average price of $24.90 per share, for a total transaction of $159,036.30.
• On Monday, May 11th, Ra Capital Management, L.P. acquired 39,869 shares of Hemab Therapeutics stock. The stock was acquired at an average cost of $24.81 per share, for a total transaction of $989,149.89.
• On Friday, May 8th, Ra Capital Management, L.P. bought 1,483 shares of Hemab Therapeutics stock. The shares were bought at an average price of $24.98 per share, for a total transaction of $37,045.34.
• On Thursday, May 7th, Ra Capital Management, L.P. purchased 9,906 shares of Hemab Therapeutics stock. The stock was purchased at an average price of $24.46 per share, for a total transaction of $242,300.76.
• On Wednesday, May 6th, Ra Capital Management, L.P. acquired 68,018 shares of Hemab Therapeutics stock. The stock was acquired at an average cost of $24.60 per share, for a total transaction of $1,673,242.80.
• On Tuesday, May 5th, Ra Capital Management, L.P. bought 97,411 shares of Hemab Therapeutics stock. The stock was bought at an average price of $24.63 per share, for a total transaction of $2,399,232.93.
• On Monday, May 4th, Ra Capital Management, L.P. purchased 2,675,000 shares of Hemab Therapeutics stock. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $48,150,000.00.

Hemab Therapeutics Stock Performance

COAG stock opened at $29.24 on Friday. Hemab Therapeutics Holdings, Inc. has a 1-year low of $23.00 and a 1-year high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last posted its quarterly earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share for the quarter.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. HC Wainwright assumed coverage on shares of Hemab Therapeutics in a report on Wednesday. They set a “buy” rating and a $40.00 target price on the stock. Wedbush assumed coverage on Hemab Therapeutics in a research note on Tuesday, May 26th. They set an “outperform” rating and a $42.00 target price on the stock. Wall Street Zen upgraded shares of Hemab Therapeutics to a “hold” rating in a research report on Saturday, May 9th. The Goldman Sachs Group began coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They issued a “buy” rating and a $36.00 price objective for the company. Finally, Zacks Research raised shares of Hemab Therapeutics to a “hold” rating in a research note on Wednesday, May 27th. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, Hemab Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $41.40.

Hemab Therapeutics News Summary

Here are the key news stories impacting Hemab Therapeutics this week:

• Positive Sentiment: HC Wainwright began coverage of Hemab Therapeutics with a Buy rating and a $40 price target, signaling analyst confidence in the company’s longer-term upside. Article Title
• Positive Sentiment: Ra Capital Management, Hemab’s major shareholder, continued adding to its stake with multiple purchases, including 61,523 shares and 6,146 shares, which can be read as a strong insider vote of confidence. Article Title
• Neutral Sentiment: HC Wainwright’s earnings estimates for 2026 through 2030 remain deeply negative, indicating Hemab is still expected to post significant losses as it remains a clinical-stage biotech company. Article Title
• Neutral Sentiment: Several comparison and analyst update articles on Hemab and peer Prime Medicine were published, but they do not appear to introduce new company-specific operational news. Article Title

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.